Michelle Kinder

1.9k total citations · 1 hit paper
21 papers, 1.5k citations indexed

About

Michelle Kinder is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Michelle Kinder has authored 21 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Michelle Kinder's work include Immune Cell Function and Interaction (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (4 papers). Michelle Kinder is often cited by papers focused on Immune Cell Function and Interaction (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (4 papers). Michelle Kinder collaborates with scholars based in United States, Belgium and United Kingdom. Michelle Kinder's co-authors include Hsiaoju Lee, J. Michael White, Gavin P. Dunn, Ulrich Kalinke, Kenneth M. Murphy, Cora D. Arthur, Hirokazu Matsushita, Mark S. Diamond, Mona Mashayekhi and Robert D. Schreiber and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Michelle Kinder

17 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

2011 864 citations Mark S. Diamond, Michelle Kinder et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michelle Kinder United States	13	1.0k	600	429	141	122	21	1.5k
Junrong Xia United States	6	1.6k 1.5×	842 1.4×	304 0.7×	101 0.7×	81 0.7×	6	2.0k
Toshihiko Ishii Japan	21	769 0.8×	371 0.6×	461 1.1×	100 0.7×	61 0.5×	41	1.5k
Nikita Kolhatkar United States	13	1.2k 1.2×	682 1.1×	433 1.0×	66 0.5×	219 1.8×	18	1.8k
Takayuki Ohkuri Japan	22	1.5k 1.4×	976 1.6×	583 1.4×	87 0.6×	131 1.1×	56	2.0k
Stephen E. Maher United States	22	844 0.8×	338 0.6×	532 1.2×	152 1.1×	128 1.0×	35	1.4k
Stephen B. Gauld United States	21	1.2k 1.2×	296 0.5×	361 0.8×	219 1.6×	69 0.6×	40	1.8k
Sinéad M. Lougheed Netherlands	22	1.0k 1.0×	644 1.1×	342 0.8×	92 0.7×	53 0.4×	37	1.3k
Stefano Sammicheli Sweden	14	1.4k 1.4×	901 1.5×	384 0.9×	57 0.4×	145 1.2×	23	2.0k
Belinda Palermo Italy	20	1.4k 1.4×	705 1.2×	304 0.7×	56 0.4×	90 0.7×	42	1.9k
Kerstin Siegmund Austria	17	1.5k 1.5×	380 0.6×	280 0.7×	96 0.7×	70 0.6×	35	1.9k

Countries citing papers authored by Michelle Kinder

Since Specialization

Citations

This map shows the geographic impact of Michelle Kinder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Kinder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Kinder more than expected).

Fields of papers citing papers by Michelle Kinder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Kinder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Kinder. The network helps show where Michelle Kinder may publish in the future.

Co-authorship network of co-authors of Michelle Kinder

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Kinder. A scholar is included among the top collaborators of Michelle Kinder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Kinder. Michelle Kinder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lorusso, Domenica, Silvia Damian, Ilaria Colombo, et al.. (2025). Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer.. Journal of Clinical Oncology. 43(16_suppl). 5603–5603.

Damian, Silvia, Domenica Lorusso, Krisztián Homicskó, et al.. (2025). Safety and preliminary efficacy from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with advanced platinum-resistant and refractory ovarian cancer (OC).. Journal of Clinical Oncology. 43(16_suppl). 5514–5514.

Kinder, Michelle, Lu Jin, Justine Carl, et al.. (2025). Abstract 4861: INCA33890 increases CD8+ T-cell effector function compared with pembrolizumab as assessed by single-cell RNA sequencing in human PD-1xTGFβR2 knock-in mouse model. Cancer Research. 85(8_Supplement_1). 4861–4861.

Guan, Jun, Aidan G. Gilmartin, Kenji Kimura, et al.. (2025). Abstract 6071: PD-1xTGFβR2 bispecific Biclonics® antibody INCA33890 augments human T-cell effector functions in vitro and ex vivo. Cancer Research. 85(8_Supplement_1). 6071–6071.

Bezman, Natalie, Michelle Kinder, Mark Mendonça, et al.. (2018). Abstract 1727: Antitumor activity associated with dual targeting of CD38 and programmed death-1 (PD-1) pathways in preclinical models. Cancer Research. 78(13_Supplement). 1727–1727. 12 indexed citations

Chornoguz, Olesya, Karen Leander, Fred M. Kaplan, et al.. (2017). TIM-3 Engagement Promotes Effector Memory T Cell Differentiation of Human Antigen-Specific CD8 T Cells by Activating mTORC1. The Journal of Immunology. 199(12). 4091–4102. 30 indexed citations

Kinder, Michelle, Allison R. Greenplate, William R. Strohl, Robert E. Jordan, & Randall J. Brezski. (2015). An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. mAbs. 7(3). 494–504. 34 indexed citations

Brezski, Randall J., Michelle Kinder, Katharine D. Grugan, et al.. (2014). A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. mAbs. 6(5). 1265–1273. 24 indexed citations

Malia, T., A. Teplyakov, Randall J. Brezski, et al.. (2014). Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge. Proteins Structure Function and Bioinformatics. 82(8). 1656–1667. 15 indexed citations

10.

Kinder, Michelle, Allison R. Greenplate, Katharine D. Grugan, et al.. (2013). Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions. Journal of Biological Chemistry. 288(43). 30843–30854. 31 indexed citations

11.

Puré, Ellen & Michelle Kinder. (2012). Response: hematopoietic defects in 12/15-lipoxygenase–deficient mice. Blood. 119(25). 6174–6175. 1 indexed citations

12.

Diamond, Mark S., Michelle Kinder, Hirokazu Matsushita, et al.. (2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. The Journal of Experimental Medicine. 208(10). 1989–2003. 864 indexed citations breakdown →

13.

Kinder, Michelle, James E. Thompson, Cong Wei, et al.. (2010). Interferon regulatory factor-8−driven myeloid differentiation is regulated by 12/15-lipoxygenase−mediated redox signaling. Experimental Hematology. 38(11). 1036–1046.e4. 7 indexed citations

14.

Kinder, Michelle. (2010). Fatty Acid Metabolism Mediated by 12/15-Lipoxygenase is a Novel Regulator of Hematopoietic Stem Cell Function and Myelopoiesis. Scholarly Commons (University of Pennsylvania). 2 indexed citations

15.

Kinder, Michelle, Cong Wei, Suresh G. Shelat, et al.. (2010). Hematopoietic stem cell function requires 12/15-lipoxygenase–dependent fatty acid metabolism. Blood. 115(24). 5012–5022. 53 indexed citations

16.

Kinder, Michelle. (2009). The Lived Experience of Treatment for Hepatitis C. Gastroenterology Nursing. 32(6). 401–408. 20 indexed citations

17.

Zukas, Alicia, Michelle Kinder, Emma H. Wilson, et al.. (2009). 12/15-Lipoxygenase-Dependent Myeloid Production of Interleukin-12 Is Essential for Resistance to Chronic Toxoplasmosis. Infection and Immunity. 77(12). 5690–5700. 15 indexed citations

18.

Meylan, Françoise, Todd S. Davidson, Erin Kahle, et al.. (2008). The TNF-Family Receptor DR3 is Essential for Diverse T Cell-Mediated Inflammatory Diseases. Immunity. 29(1). 79–89. 174 indexed citations

19.

Zhao, Liang, Alicia Zukas, Michelle Kinder, et al.. (2008). CD44 Expressed on Both Bone Marrow–Derived and Non–Bone Marrow–Derived Cells Promotes Atherogenesis in ApoE-Deficient Mice. Arteriosclerosis Thrombosis and Vascular Biology. 28(7). 1283–1289. 32 indexed citations

20.

Kinder, Michelle, et al.. (2007). Metastatic breast cancer induces an osteoblast inflammatory response. Experimental Cell Research. 314(1). 173–183. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact